​

Aileron Therapeutics (ALRN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

ALRN Stock Rating

Aileron Therapeutics stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (80.00%), 1 Hold (20.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 1 4 Strong Sell Sell Hold Buy Strong Buy

ALRN Price Target Upside V Benchmarks

TypeNameUpside
StockAileron Therapeutics-
SectorHealthcare Stocks 24.81%
IndustryBiotech Stocks 65.78%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$2.11$2.11$2.11
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25-2---2
Dec, 24-2---2
Nov, 2442---6
Oct, 2442---6
Sep, 2442---6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-3.42----
Avg Forecast$-2.01$-1.56$-1.42$-1.78$-1.76
High Forecast$-2.01$-1.34$-0.95$-1.78$-1.76
Low Forecast$-2.01$-1.76$-1.87$-1.78$-1.76
Surprise %70.15%----

Revenue Forecast

$65M $78M $91M $104M $117M $130M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 23Dec 24Dec 25Dec 26Dec 27
Reported-----
Avg Forecast---$69.76M$127.66M
High Forecast---$69.76M$127.66M
Low Forecast---$69.76M$127.66M
Surprise %-----

Net Income Forecast

$-20M $-16M $-12M $-8M $-4M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-15.73M----
Avg Forecast$-9.25M$-7.13M$-6.48M$-8.19M$-8.09M
High Forecast$-9.25M$-6.14M$-4.35M$-8.19M$-8.09M
Low Forecast$-9.25M$-8.11M$-8.62M$-8.19M$-8.09M
Surprise %70.04%----

ALRN Forecast FAQ

Is Aileron Therapeutics stock a buy?

Aileron Therapeutics stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Aileron Therapeutics is a favorable investment for most analysts.

What is Aileron Therapeutics's price target?

Aileron Therapeutics's price target, set by 5 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $2.11.

How does Aileron Therapeutics stock forecast compare to its benchmarks?

Aileron Therapeutics's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (24.81%) and underperforming the biotech stocks industry (65.78%).

What is the breakdown of analyst ratings for Aileron Therapeutics over the past three months?

  • January 2025: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 66.67% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Aileron Therapeutics’s EPS forecast?

Aileron Therapeutics's average annual EPS forecast for its fiscal year ending in December 2024 is $-1.56, marking a -54.39% decrease from the reported $-3.42 in 2023. Estimates for the following years are $-1.42 in 2025, $-1.78 in 2026, and $-1.76 in 2027.

What is Aileron Therapeutics’s revenue forecast?

Aileron Therapeutics's average annual revenue forecast for its fiscal year ending in December 2024 is $0, reflecting a 0% decrease from the reported $0 in 2023. The forecast for 2025 is $0, followed by $69.76M for 2026, and $127.66M for 2027.

What is Aileron Therapeutics’s net income forecast?

Aileron Therapeutics's net income forecast for the fiscal year ending in December 2024 stands at $-7.128M, representing a -54.69% decrease from the reported $-15.732M in 2023. Projections indicate $-6.484M in 2025, $-8.186M in 2026, and $-8.094M in 2027.